150例青海地区非小细胞肺癌患者表皮生长因子受体突变状态分析  

Analysis on EGFR mutation status in 150 cases of non-small cell lung cancer in Qinghai region

作　　者：卢天龙[1] 杨启英[1] 

机构地区：[1]青海大学附属医院检验科,西宁810000

出　　处：《检验医学与临床》2016年第1期31-32,共2页Laboratory Medicine and Clinic

基　　金：青海省(应用)基础研究计划项目(2013-Z-735)

摘　　要：目的探讨青海地区非小细胞肺癌(NSCLC)治疗过程中表皮生长因子受体(EGFR)突变状态。方法利用实时荧光Taqman探针法,采用PCR体外扩增,回顾性分析150例晚期NSCLC患者的临床特征、EGFR突变状态。结果 150例NSCLC患者标本检测发现EGFR(exon18)突变2例,突变率1.3%;EGFR(exon19)突变18例,突变率12.0%;EGFR(exon20)未检测出;EGFR(exon21)突变27例,突变率18.0%。结论青海地区NSCLC患者EGFR基因外显子19和21的突变(体细胞突变)率较高,可接受EGFR-TKIs治疗。Objective To explore the mutation status of epidermal growth factor receptor （EGFR） during the treatment process of non-small cell lung cancer （NSCLC） in Qinghai region. Methods The real-time fluorescence Taqman probe method was used and the PCR amplification in vitro was adopted. The clinical characteristics and EG- FR mutation status in 150 cases of advance NSCLC were retrospectively analyzed. Results In the sample detection of 150 NSCLC cases, EGFR mutation （exon18） was in 2 cases with the mutation rate of 1. 3% ; EGFR mutation （ exonl 9） was in 18 cases with the mutation rate of 12.0%; EGFR （exon20） was not detected ; EGFR mutations （exon 21） was in 27 cases with the mutation rate of 18.0%. Conclusion The mutation rate of EGFR gene exon 19 and 21 （somatic mutation） is higher in NSCLC patients of Qinghai region. The EGFR-TKIs treatment is acceptable.

关 键 词：非小细胞肺癌 表皮生长因子受体 突变 

分 类 号：R737.33[医药卫生—肿瘤]